ArticleBreast cancer research and treatment2026
Exploring the potential of postmastectomy radiotherapy in cN + and ypN0 breast cancer patients following neoadjuvant chemotherapy.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to determine the potential association of postmastectomy radiotherapy and survival in patients with clinically node-positive axillary breast cancer who achieved ypN0 after neoadjuvant chemotherapy.
methodsWe conducted a retrospective cohort study using the National Cancer Database. Eligible patients were women aged 18-80 with cT1-2, cN+ invasive breast cancer and achieving ypN0 status. Inverse probability weighting (IPW)-based analyses were used to assess the differences in overall survival (OS) between the radiotherapy and no radiotherapy groups. Absolute 5-year OS rates between the two groups were analyzed by nonparametric sliding-window subpopulation treatment effect pattern plot (STEPP) analysis. Sensitivity analyses were conducted using multivariable Cox regressions.
resultsWe identified 3,351 patients who met eligibility criteria, of whom 57.0% (N = 1,910) did not receive radiotherapy and 43.0% (N = 1,441) did receive radiotherapy. No significant differences in OS were observed between the radiotherapy and non-radiotherapy groups after adjustment (hazard ratio = 1.01, P = .96). The STEPP analysis demonstrated no significant differences between the RT and no RT groups, regardless of the composite risk. Subgroup analyses showed that the difference in OS rates between the two groups was significantly correlated with cN category, and the advantage associated with radiotherapy receipt was only observed in cN2-3 patients but not in cN1 patients (hazard ratio = 0.55; P-interaction = 0.024).
conclusionsThis study further supports the NSABP B51 findings, suggesting that omitting postmastectomy radiotherapy may be reasonable for cT1-2N1M0 patients who achieved ypN0. However, postmastectomy radiotherapy may be a consideration for patients with more advanced nodal disease (cN2-3) who achieve ypN0 status after NAC, indicating that a more tailored approach may be warranted.
Indexed as
Identifiers
42118193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.